A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, single-dose study to compare the PK of 21 desacetyl-DFZ
and, if data permits, deflazacort in 8 subjects with ESRD to that of 8 healthy matched
control subjects (age, body mass index [BMI], and gender).